Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 85,424	$ 194,905
Short-term investments	1,429,955	1,140,445
Accounts receivable	37,299	43,213
Inventory	13,188	11,381
Advance payments to contract manufacturers	17,738	26,450
Other current assets	13,213	21,293
Total current assets	1,596,817	1,437,687
Long-term investments	276,305	582,889
Property, plant and equipment, net	65,453	48,851
Operating lease right-of-use assets	82,177	0
Goodwill	76,501	76,501
Other assets	2,400	4,244
Total assets	2,099,653	2,150,172
Current liabilities:
Accounts payable	9,346	5,854
Accrued compensation	19,710	9,937
Accrued clinical trial expenses	29,540	14,700
Accrued contract manufacturing expenses	23,159	23,841
Other accrued expenses	13,830	9,580
Interest payable	4,144	4,198
Operating lease liabilities, current portion	3,749	0
Deferred revenue, current portion	9,892	13,892
Total current liabilities	113,370	82,002
Senior secured notes, net	247,821	246,950
Operating lease liabilities, less current portion	94,822	0
Liability related to the sale of future royalties, net	77,813	82,911
Deferred revenue, less current portion	8,029	10,744
Other long-term liabilities	643	9,990
Total liabilities	542,498	432,597
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at June 30, 2019 or December 31, 2018	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 174,966 shares and 173,530 shares outstanding at June 30, 2019 and December 31, 2018, respectively	17	17
Capital in excess of par value	3,210,398	3,147,925
Accumulated other comprehensive loss	(788)	(6,316)
Accumulated deficit	(1,652,472)	(1,424,051)
Total stockholders’ equity	1,557,155	1,717,575
Total liabilities and stockholders’ equity	$ 2,099,653	$ 2,150,172